Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Kyowa Hakko Kirin Co Ltd    4151   JP3256000005

KYOWA HAKKO KIRIN CO LTD (4151)
Mes dernières consult.
Most popular
  Report  
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (JPY)
Sales 2018 344 B
EBIT 2018 -
Net income 2018 48 907 M
Finance 2018 72 953 M
Yield 2018 1,38%
Sales 2019 365 B
EBIT 2019 -
Net income 2019 47 606 M
Finance 2019 96 553 M
Yield 2019 1,47%
P/E ratio 2018 24,48
P/E ratio 2019 25,68
EV / Sales2018 3,39x
EV / Sales2019 3,13x
Capitalization 1 239 B
More Financials
Company
Kyowa Hakko Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products.It operates through the Pharmaceuticals and Bio-Chemicals segments.The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro diagnostic reagents and... 
Sector
Pharmaceuticals
Calendar
07/31Earnings Release
More about the company
Surperformance© ratings of Kyowa Hakko Kirin Co Ltd
Trading Rating : Investor Rating :
More Ratings
Latest news on KYOWA HAKKO KIRIN CO LTD
07/12KYOWA HAKKO KIRIN : Patent Application Titled "Method for Purifying Mitomycin C"..
AQ
06/27KYOWA HAKKO KIRIN CO LTD : Ex-dividend day for interim dividend
FA
06/06KYOWA HAKKO KIRIN : Kirin Presents New Data for Mogamulizumab from Its Lead Prog..
AQ
06/05Reata Announces That Kyowa Hakko Kirin Initiated Ayame, a Phase 3 Trial of Ba..
AQ
06/04KYOWA HAKKO KIRIN : Announces FDA Notification of PDUFA Action Date Extension fo..
AQ
06/04Kyowa Hakko Kirin Initiated Phase 3 Clinical Study of Bardoxolone Methyl for ..
AQ
05/31KYOWA HAKKO KIRIN : Patent Issued for Method for Preventing Reduction of Polypep..
AQ
05/24Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demo..
AQ
05/24Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demo..
AQ
05/22Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results
AQ
More news
Sector news : Specialty & Advanced Pharmaceuticals
07/20GLAXOSMITHKLINE : considers splitting up the group - FT
RE
07/20PFIZER : Biosimilar of Amgen's Neupogen Approved for Sale in the U.S.
DJ
07/20BAYER : to Stop Selling Essure in U.S.
DJ
07/20GLAXOSMITHKLINE : considers splitting up the group
RE
07/20GLAXOSMITHKLINE : Mulls Separation of Consumer Division -- FT
DJ
More sector news : Specialty & Advanced Pharmaceuticals
Latest Tweets
06/04Reata $RETA Announces That Kyowa Hakko Kirin Initiated Ayame, a Phase 3 Trial.. 
06/04$RETA: Reata Pharmaceuticals licensee, Kyowa Hakko Kirin Co., Ltd., has initi.. 
06/04Reata Announces That Kyowa Hakko Kirin Initiated Ayame, a Phase 3 Trial of Ba.. 
06/04Reata Announces That Kyowa Hakko Kirin Initiated Ayame, a Phase 3 Trial of Ba.. 
05/17Ultragenyx and Kyowa Hakko Kirin's Crysvita beats conventional therapy in lat.. 
More tweets
Qtime:15
News from SeekingAlpha
06/23What Does Breakthrough Therapy Designation Really Mean For My Company? 
02/09Kyowa Hakko Kogyo Co., Ltd. ADR 2017 Q4 - Results - Earnings Call Slides 
2017YOUR DAILY PHARMA SCOOP : Omeros If And Buts, Egalet's Oxycodone Success, Auris .. 
2017Ardelyx and Kyowa Hakko Kirin inks deal for Tenapanor for Cardiorenal disease.. 
2017FDA grants priority review status to Kyowa Hakko Kirin's BLA for Mogamulizuma.. 
Chart KYOWA HAKKO KIRIN CO LTD
Duration : Period :
Kyowa Hakko Kirin Co Ltd Technical Analysis Chart | 4151 | JP3256000005 | 4-Traders
Technical analysis trends KYOWA HAKKO KIRIN CO LTD
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 2 572  JPY
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Nobuo Hanai Chairman & Chief Executive Officer
Masashi Miyamoto President, COO & Representative Director
Yoichi Sato Director, Managing Executive Officer, GM-R&D
Kazuyoshi Tachibana Director & Managing Executive Officer
Toshifumi Mikayama Director & Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
KYOWA HAKKO KIRIN CO LTD-2.57%11 111
ABBVIE-8.07%142 740
MERCK KGAA-4.36%13 006
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD93.01%10 926
JAZZ PHARMACEUTICALS PLC31.07%10 677
CONVATEC GROUP-0.24%5 232